ACR16: Completed Phase III enrollment

NeuroSearch completed enrollment of 420 patients in the double-blind, placebo-controlled, European Phase III MermaiHD trial evaluating 45 mg of oral ACR16 given once or twice daily for 26 weeks. Neuro...